Active Substance: Ranitidine (as HCl).
Overview
Welcome to Dwaey, specifically on RANZIN 150 page.
This medicine contains an important and useful components, as it consists of
Ranitidine (as HCl)is available in the market in concentration
Ranitidine
Possibility of malignancy should be excluded prior to therapy as the drug may mask symptoms and delay diagnosis of gastric malignancy. Patients w/ difficulty in swallowing. Renal and hepatic impairment. Pregnancy and lactation. Lactation: Drug crosses into breast milk; discontinue drug, use caution
Dyspepsia, H. pylori infection, Benign gastric and duodenal ulceration, GERD, Acid aspiration during general anesth, Prophylaxis during NSAID treatment, Stress ulceration of upper GI, Zollinger-Ellison syndrome
Porphyria.
1-10% Headache (3%) <1% Abdominal pain,Agitation,Alopecia,Confusion,Constipation,Diarrhea,Dizziness,Hypersensitivity reaction,Nausea,Vomiting Frequency Not Defined Anemia,Necrotizing enterocolitis in fetus or newborn,Pancreatitis (rare),Thrombocytopenia (rare),Pancytopenia (rare),Agranulocytosis (rare),Acquired immune hemolytic anemia (rare),Arthralgia (rare),Myalgia (rare) Potentially Fatal: Anaphylaxis, hypersensitivity reactions.
2
Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
Delayed absorption and increased peak serum concentration w/ propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability w/ antacids.
Information not available